CHRISTIE BALLANTYNE to Hyperlipoproteinemia Type II
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Hyperlipoproteinemia Type II.
Connection Strength
9.039
-
The impact of genetic testing on physician practice in specialized cardiovascular clinics. J Clin Lipidol. 2026 Mar; 20(3):677-681.
Score: 0.873
-
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 01 13; 335(2):129-139.
Score: 0.871
-
Simulation model to estimate pretreatment (baseline) low-density lipoprotein cholesterol levels in people living with homozygous familial hypercholesterolemia. J Clin Lipidol. 2025 Sep-Oct; 19(5):1457-1462.
Score: 0.847
-
Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study). Am J Cardiol. 2022 07 01; 174:1-11.
Score: 0.673
-
Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2019 01; 280:109-117.
Score: 0.530
-
Dyslipidaemia: PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia. Nat Rev Cardiol. 2017 07; 14(7):385-386.
Score: 0.477
-
Familial Hypercholesterolemia and the 2013 American College of Cardiology/American Heart Association Guidelines: Myths, Oversimplification, and Misinterpretation Versus Facts. Am J Cardiol. 2015 Aug 01; 116(3):481-4.
Score: 0.415
-
The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia. Curr Atheroscler Rep. 2015 May; 17(5):508.
Score: 0.415
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
Score: 0.220
-
The evolving therapeutic landscape of PCSK9 inhibition. Atherosclerosis. 2026 Mar; 414:120670.
Score: 0.219
-
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2026 Feb; 14(2):123-136.
Score: 0.217
-
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. J Am Coll Cardiol. 2025 Oct 07; 86(14):1046-1056.
Score: 0.212
-
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 03; 393(1):51-61.
Score: 0.208
-
It is Time to Screen for Homozygous Familial Hypercholesterolemia in the United States. Glob Heart. 2024; 19(1):43.
Score: 0.194
-
Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals With Elevated Cholesterol. JAMA Cardiol. 2024 Mar 01; 9(3):263-271.
Score: 0.191
-
Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease. Circulation. 2023 05 16; 147(20):1556-1559.
Score: 0.181
-
Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. J Am Heart Assoc. 2023 05 02; 12(9):e029175.
Score: 0.180
-
Reply: Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia. J Clin Lipidol. 2023 Mar-Apr; 17(2):304-305.
Score: 0.178
-
Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia. J Clin Lipidol. 2023 Jan-Feb; 17(1):150-156.
Score: 0.175
-
Familial hypercholesterolaemia: optimum treatment strategies. Int J Clin Pract Suppl. 2002 Jul; (130):22-6.
Score: 0.170
-
Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia. J Am Heart Assoc. 2021 09 07; 10(17):e020890.
Score: 0.161
-
Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
Score: 0.159
-
Clinical Genetic Testing for Familial?Hypercholesterolemia: JACC Scientific Expert Panel. J Am Coll Cardiol. 2018 08 07; 72(6):662-680.
Score: 0.130
-
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
Score: 0.126
-
Health disparities among adult patients with a phenotypic diagnosis of familial hypercholesterolemia in the CASCADE-FH? patient registry. Atherosclerosis. 2017 Dec; 267:19-26.
Score: 0.123
-
US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol. 2016 Sep-Oct; 10(5):1223-9.
Score: 0.113
-
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet. 2016 Jun; 9(3):240-9.
Score: 0.110
-
Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry. Am Heart J. 2014 Mar; 167(3):342-349.e17.
Score: 0.094
-
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S1-8.
Score: 0.078
-
Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun; 5(3 Suppl):S9-17.
Score: 0.078
-
Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 May-Jun; 5(3):133-140.
Score: 0.078
-
Carotid atherosclerosis progression in familial hypercholesterolemia patients: a pooled analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE studies. Circ Cardiovasc Imaging. 2010 Jul; 3(4):398-404.
Score: 0.074
-
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol. 2007 Nov 01; 100(9):1387-96.
Score: 0.061
-
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol. 2005 May 17; 45(10):1611-9.
Score: 0.052
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
Score: 0.048
-
Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholesterolemia. Clin Chem. 2002 Nov; 48(11):1913-8.
Score: 0.044
-
Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. J Clin Lipidol. 2018 Sep - Oct; 12(5):1141-1145.
Score: 0.032
-
A simplified pathway to proprotein convertase subtilisin/kexin type 9 inhibitor prior authorization approval: A lipid clinic experience. J Clin Lipidol. 2017 May - Jun; 11(3):596-599.
Score: 0.029